Health Care Fund
Daily price w/o sales charge as of 04/25/2025
$18.36
$0.12
YTD Returns w/o sales charge as of 04/25/2025
-5.51%
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 03/31/2025
- Total Net Assets
- $7.49 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 2.99%
- Fund Net Expense Ratio
- 0.68%
- Number of Holdings
- 66
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
YTD |
1-YR |
3-YR |
5-YR |
10-YR |
Since Inception 07/31/2019 |
|
---|---|---|---|---|---|---|
w/o sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Lipper Category Avg. Health/Biotechnology Funds | -1.51% | -6.79% | -0.25% | 7.46% | - | - |
MSCI ACWI Health Care Index (Net) | 4.95% | -0.92% | 2.34% | 9.45% | - | 8.39% |
w/ sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
YTD |
1-YR |
3-YR |
5-YR |
10-YR |
Since Inception 07/31/2019 |
|
---|---|---|---|---|---|---|
w/o sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Lipper Category Avg. Health/Biotechnology Funds | -1.51% | -6.79% | -0.25% | 7.46% | - | - |
MSCI ACWI Health Care Index (Net) | 4.95% | -0.92% | 2.34% | 9.45% | - | 8.39% |
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM




Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
YTD |
1-YR |
3-YR |
5-YR |
10-YR |
Since Inception 07/31/2019 |
|
---|---|---|---|---|---|---|
w/o sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Lipper Category Avg. Health/Biotechnology Funds | -1.51% | -6.79% | -0.25% | 7.46% | - | - |
MSCI ACWI Health Care Index (Net) | 4.95% | -0.92% | 2.34% | 9.45% | - | 8.39% |
w/ sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
YTD |
1-YR |
3-YR |
5-YR |
10-YR |
Since Inception 07/31/2019 |
|
---|---|---|---|---|---|---|
w/o sales charge | -4.99% | -5.80% | 0.39% | 9.49% | - | 7.52% |
Lipper Category Avg. Health/Biotechnology Funds | -1.51% | -6.79% | -0.25% | 7.46% | - | - |
MSCI ACWI Health Care Index (Net) | 4.95% | -0.92% | 2.34% | 9.45% | - | 8.39% |
Fund Expense Ratio :
Gross 2.99%
Net 0.68%
Past performance is not a reliable indicator or guarantee of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost.
NAV Historical Prices
Date | Net Asset Value |
---|
Portfolio
Portfolio
Portfolio Details as of 03/31/2025
- Total Net Assets
- $7.49 M
- Number of Holdings
- 66
- Weighted Average Market Cap.
- 127.2 B
- P/B Ratio
- 6.5x
- P/E Ratio
- 44.2x
To view definitions for the above Portfolio Details, Click here.
Holding | Sector | Assets |
---|
Holding |
Sector |
Assets |
---|---|---|
Eli Lilly & Co | Health Care | 8.6% |
Boston Scientific Corp | Health Care | 4.8% |
Intuitive Surgical Inc | Health Care | 4.7% |
Gilead Sciences Inc | Health Care | 3.9% |
Stryker Corp | Health Care | 3.7% |
Argenx SE | Health Care | 3.5% |
Natera Inc | Health Care | 3.0% |
Tarsus Pharmaceuticals Inc | Health Care | 2.9% |
Cencora Inc | Health Care | 2.6% |
UCB SA | Health Care | 2.1% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Holding | Sector | Assets |
---|
Holding |
Sector |
Assets |
---|---|---|
Eli Lilly & Co | Health Care | 8.1% |
Intuitive Surgical Inc | Health Care | 4.7% |
Boston Scientific Corp | Health Care | 4.6% |
Gilead Sciences Inc | Health Care | 3.7% |
Argenx SE | Health Care | 3.4% |
Stryker Corp | Health Care | 3.3% |
Natera Inc | Health Care | 3.1% |
Tarsus Pharmaceuticals Inc | Health Care | 2.3% |
Cencora Inc | Health Care | 2.2% |
Novo Nordisk A/S | Health Care | 2.0% |
Glaukos Corp | Health Care | 1.9% |
Pharma Mar SA | Health Care | 1.8% |
UCB SA | Health Care | 1.7% |
UnitedHealth Group Inc | Health Care | 1.7% |
Doximity Inc | Health Care | 1.6% |
Lonza Group AG | Health Care | 1.6% |
Blueprint Medicines Corp | Health Care | 1.6% |
Insulet Corp | Health Care | 1.5% |
Swedish Orphan Biovitrum AB | Health Care | 1.5% |
Alcon AG | Health Care | 1.4% |
Insmed Inc | Health Care | 1.4% |
Zealand Pharma A/S | Health Care | 1.4% |
GeneDx Holdings Corp | Health Care | 1.3% |
Globus Medical Inc | Health Care | 1.3% |
Terumo Corp | Health Care | 1.3% |
Mirum Pharmaceuticals Inc | Health Care | 1.2% |
Galderma Group AG | Health Care | 1.2% |
AstraZeneca PLC | Health Care | 1.2% |
Encompass Health Corp | Health Care | 1.2% |
ADMA Biologics Inc | Health Care | 1.2% |
SpringWorks Therapeutics Inc | Health Care | 1.2% |
Scholar Rock Holding Corp | Health Care | 1.2% |
Penumbra Inc | Health Care | 1.2% |
United Therapeutics Corp | Health Care | 1.1% |
Ceribell Inc | Health Care | 1.1% |
Arcellx Inc | Health Care | 1.0% |
Nuvalent Inc | Health Care | 1.0% |
Repligen Corp | Health Care | 1.0% |
PROCEPT BioRobotics Corp | Health Care | 1.0% |
Daiichi Sankyo Co Ltd | Health Care | 1.0% |
Guardant Health Inc | Health Care | 1.0% |
Agilent Technologies Inc | Health Care | 0.9% |
Cooper Cos Inc/The | Health Care | 0.9% |
Revolution Medicines Inc | Health Care | 0.9% |
Verona Pharma PLC | Health Care | 0.9% |
CareDx Inc | Health Care | 0.9% |
Xenon Pharmaceuticals Inc | Health Care | 0.8% |
Abbott Laboratories | Health Care | 0.8% |
Waystar Holding Corp | Health Care | 0.8% |
Madrigal Pharmaceuticals Inc | Health Care | 0.8% |
Thermo Fisher Scientific Inc | Health Care | 0.8% |
GE HealthCare Technologies Inc | Health Care | 0.7% |
Bridgebio Pharma Inc | Health Care | 0.7% |
Janux Therapeutics Inc | Health Care | 0.7% |
Straumann Holding AG | Health Care | 0.7% |
Vericel Corp | Health Care | 0.7% |
Bio-Techne Corp | Health Care | 0.7% |
Akero Therapeutics Inc | Health Care | 0.7% |
Vera Therapeutics Inc | Health Care | 0.7% |
Veracyte Inc | Health Care | 0.7% |
Teva Pharmaceutical Industries Ltd | Health Care | 0.6% |
Krystal Biotech Inc | Health Care | 0.6% |
Evolus Inc | Health Care | 0.5% |
Telix Pharmaceuticals Ltd | Health Care | 0.5% |
Rhythm Pharmaceuticals Inc | Health Care | 0.5% |
Crinetics Pharmaceuticals Inc | Health Care | 0.5% |
Vaxcyte Inc | Health Care | 0.5% |
Artivion Inc | Health Care | 0.4% |
Twist Bioscience Corp | Health Care | 0.4% |
Tempus AI Inc | Health Care | 0.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Fees & Expenses
Fees & Expenses
Expense Ratioas of 03/31/2025
Fund Gross Expense Ratio | 2.99% |
Fund Net Expense Ratio | 0.68% |
Expense ratio details, Click here.
Fund Documents
Fund Documents
0Documents selected
|
||||
---|---|---|---|---|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
Summary Prospectus
Publish Date:11/03/2015
|
||||
Statutory Prospectus
Publish Date:11/03/2015
|
||||
SAI
Publish Date:11/03/2015
|
||||
Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
Annual Tailored Shareholder Report
Publish Date:11/03/2015
|
||||
Semi-Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
Fact Sheet
Publish Date:11/03/2015
|